Kevin Donahue reports 10.7% stake in Mainz Biomed
Mainz Biomed N.V. shareholder Kevin Donahue has filed an amended Schedule 13G reporting beneficial ownership of the company’s common stock.
Rhea-AI Filing Summary
Mainz Biomed N.V. shareholder Kevin Donahue has filed an amended Schedule 13G reporting beneficial ownership of the company’s common stock. He reports holding 685,000 shares of Mainz Biomed common stock, representing 10.7% of the class, with the event triggering the filing dated 10/17/2025. Donahue has sole voting and sole dispositive power over all 685,000 shares, and no shared voting or shared dispositive power is reported. The filing is made in his capacity as an individual investor and indicates that he continues to own more than 5% of the company’s outstanding common stock.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in MYNZ does Kevin Donahue report?
What type of filing did Mainz Biomed investor Kevin Donahue submit?
When was the ownership event that required this MYNZ Schedule 13G/A filing?
Is Kevin Donahue reporting ownership in Mainz Biomed N.V. as part of a group?
What class of securities of Mainz Biomed N.V. is covered in this Schedule 13G/A?
AI-generated analysis. How Rhea-AI works. Not financial advice.